Pharmaceuticals (Jul 2021)

Bioactive Compounds from <i>Euphorbia usambarica</i> Pax. with HIV-1 Latency Reversal Activity

  • Yu-Chi Tsai,
  • Racheal A. Nell,
  • Jonathan E. Buckendorf,
  • Norbert Kúsz,
  • Peter Waweru Mwangi,
  • Róbert Berkecz,
  • Dóra Rédei,
  • Andrea Vasas,
  • Adam M. Spivak,
  • Judit Hohmann

DOI
https://doi.org/10.3390/ph14070653
Journal volume & issue
Vol. 14, no. 7
p. 653

Abstract

Read online

Euphorbia usambarica is a traditional medicine used for gynecologic, endocrine, and urogenital illnesses in East Africa; however, its constituents and bioactivities have not been investigated. A variety of compounds isolated from Euphorbia species have been shown to have activity against latent HIV-1, the major source of HIV-1 persistence despite antiretroviral therapy. We performed bioactivity-guided isolation to identify 15 new diterpenoids (1–9, 14–17, 19, and 20) along with 16 known compounds from E. usambarica with HIV-1 latency reversal activity. Euphordraculoate C (1) exhibits a rare 6/6/3-fused ring system with a 2-methyl-2-cyclopentenone moiety. Usambariphanes A (2) and B (3) display an unusual lactone ring constructed between C-17 and C-2 in the jatrophane structure. 4β-Crotignoid K (14) revealed a 250-fold improvement in latency reversal activity compared to crotignoid K (13), identifying that configuration at the C-4 of tigliane diterpenoids is critical to HIV-1 latency reversal activity. The primary mechanism of the active diterpenoids 12–14 and 21 for the HIV-1 latency reversal activity was activation of PKC, while lignans 26 and 27 that did not increase CD69 expression, suggesting a non-PKC mechanism. Accordingly, natural constituents from E. usambarica have the potential to contribute to the development of HIV-1 eradication strategies.

Keywords